Use of nucleic acids with reduced pressure therapy

Patent metadata

Field	Value
Publication number	US-2016206755-A1
Application number	US-201615082683-A
Country	US
Kind code	A1
Filing date	Mar 28, 2016
Priority date	Apr 30, 2008
Publication date	Jul 21, 2016
Grant date	—

Abstract

Provided is a method of treating a wound site. Also provided is a system for treating a wound site. Additionally provided is the use of reduced pressure and a nucleic acid that promotes wound healing for treatment of a wound site. Further provided is the use of a nucleic acid that promotes wound healing for the manufacture of a medicament for treating a wound site that is undergoing reduced pressure treatment.

First claim

We claim:

1 . A method of treating a wound site, the method comprising
applying a nucleic acid that promotes wound healing to the wound site, and applying a reduced pressure to the wound site.

2 . The method of claim 1 , wherein the wound site comprises dermal tissue, bone tissue, cartilage, tendon, ligament, nerve tissue, or adipose tissue.

3 . The method of claim 1 , wherein the nucleic acid encodes a protein.

4 . The method of claim 3 , wherein the nucleic acid is operably linked to a control element that directs expression of the protein when the nucleic acid is inside a cell in the wound site.

5 . The method of claim 3 , wherein the protein is a structural protein, an enzyme, an enzyme inhibitor, a cell surface receptor or a transcription factor.

6 . The method of claim 5 , wherein the protein is a collagen, a fibronectin, an elastin, a laminin, a Tie-1, a Tie-2, a c-kit, an HIF-1α, a tissue inhibitor of metalloproteinase, an integrin, a HoxD3, an hypoxia-inducible factor-1α (HIF-1α), or a Net.

7 . The method of claim 3 , wherein the protein is a cytokine.

8 . The method of claim 7 , wherein the cytokine is a fibroblast growth factor (FGF), a vascular endothelial growth factor (VEGF), a platelet derived growth factor (PDGF), a transforming growth factor-β (TGFβ), a TGFα, a stem cell factor (SCF), an angiopoietin 1 (Ang1), an epidermal growth factor (EGF), an interleukin, an insulin-like growth factor (IGF), a laminin, a hepatocyte growth factor (HGF), an adrenomedullin, a keratinocyte growth factor (KGF), a bone morphogenic protein (BMP), a cartilage derived morphogenic protein (CDMP), or a placental growth factor (PIGF).

9 . The method of claim 3 , wherein the nucleic acid encodes a protein that increases expression in response to reduced pressure treatment of the wound site.

10 . The method of claim 9 , wherein the protein is interleukin 6 (IL-6), chemokine ligand 7 (Ccl7), tissue inhibitor of metalloproteinase 1 (TIMP1), integrin alpha M (Itgam), suppressor of cytokine signaling 3 (Socs3), matrix metalloproteinase-8 (MMP-8), macrophage inflammatory protein-1 alpha receptor (MIP1), toll like receptor 1 (TLR1), tumor necrosis factor receptor superfamily member 1b (Tnfrsf1b), heat shock protein 70 (Hsp70), calmodulin-like 3, or keratin complex 1 acidic 14 (Krt1-14).

11 . The method of claim 1 , wherein the nucleic acid specifically inhibits expression of a protein that inhibits wound healing.

12 . The method of claim 11 , wherein the protein that inhibits wound healing is a small mothers against decapentaplegic homolog 3 (Smad3), a vascular endothelial growth factor receptor 1 (VEGFR1), a VEGFR2, a VEGFR3, a connexin, or a myostatin.

13 . The method of claim 11 , wherein the nucleic acid is an antisense nucleic acid specific to an mRNA encoding the protein.

14 . The method of claim 11 , wherein the nucleic acid is, or encodes, (a) a ribozyme or an miRNA specific to an mRNA encoding the protein, or (b) an aptamer that specifically binds and inhibits a protein that inhibits wound healing.

15 . The method of claim 11 , wherein the nucleic acid inhibits a naturally occurring miRNA that inhibits wound healing.

16 . The method of claim 15 , wherein the naturally occurring miRNA inhibits expression of VEGF.

17 . The method of claim 1 , wherein the nucleic acid is part of a viral vector or a plasmid.

18 . The method of claim 1 , wherein the reduced pressure is provided by an apparatus that comprises a dressing that contacts the wound site.

19 . The method of claim 18 , wherein the nucleic acid is on or in the dressing such that the nucleic acid is transmitted to the wound site.

20 . A system for treating a wound at a wound site, comprising:
a distribution manifold; a reduced pressure source fluidly connected to said distribution manifold to deliver reduced pressure to the wound site; and a nucleic acid source fluidly connected to said distribution manifold to deliver nucleic acid to the wound site sufficient to treat the wound.

Assignees

• Kci Licensing Inc

Inventors

• Mcnulty Amy
• Kieswetter Kristine

Classifications

• A61K48/0083

  characterised by an aspect of the administration regime · CPC title

• C07H21/04

  with deoxyribosyl as saccharide radical · CPC title

• A61P17/02

  for treating wounds, ulcers, burns, scars, keloids, or the like · CPC title

• A61F13/00

  Bandages or dressings (radioactive dressings {A61N5/1029}); Absorbent pads · CPC title

• A61K38/02

  Peptides of undefined number of amino acids; Derivatives thereof · CPC title